30-Second Takeaway
- Half of registry severe asthma patients remain poorly controlled despite biologic-era care, strongly shaped by lung function, exacerbations, and socioeconomic status.
- Early-life viral LRTIs and RSV-family infections imprint pathogenic Th2 tissue-resident memory that mechanistically link infancy bronchiolitis to later asthma.
- Multiple epithelial–immune axes (TSLP, S1P/S1PR3, NETs, MUC5AC) emerge as actionable targets across asthma, CRS with polyps, and atopic dermatitis.
- Preclinical platforms highlight druggable nodes—sPLA2-X, itaconate signaling, MUC5AC siRNA, Lyn kinase—that may complement current biologics.
- Diet- and metabolite-derived small molecules modulating mast cells, neutrophils, and Th17 responses could inform future adjunctive therapies in allergic disease.
Week ending March 14, 2026
From severe asthma control gaps to epithelial-immune crosstalk: emerging targets across the allergic airway continuum
Half of Korean registry severe asthma patients remain poorly controlled despite biologic-era care
Among 594 adults in the Korean Severe Asthma Registry-2, 51.9% had poorly controlled disease by ACT <20 at baseline. Poor control strongly associated with receiving medical aid, underweight status, FEV1 <60% predicted, and prior exacerbations. Type 2 inflammation markers paradoxically associated with better control, suggesting non–T2-driven mechanisms dominate many poorly controlled cases. Biologic use itself was not linked to control status, highlighting unmet need in socioeconomic support and multidimensional risk stratification.
sPLA2-X acts as an endogenous adjuvant driving atopic march–like airway disease
In a dermal sensitization–airway challenge mouse model, Pla2g10 deficiency reduced airway hyperresponsiveness and eosinophilia after house dust mite exposure. Human sPLA2-X transgenic mice treated with a small-molecule sPLA2-X inhibitor during skin sensitization developed less AHR and lung eosinophilia. Inhibition also reduced lung dust mite–specific tissue-resident memory CD4+ T cells, implicating sPLA2-X in establishing durable allergic memory. These data position sPLA2-X inhibition during peripheral sensitization as a potential strategy to prevent allergen-induced asthma.
Noninflammatory LNP–siRNA platform potently silences MUC5AC and improves asthma phenotypes in mice
Investigators engineered low-immunogenicity lipid nanoparticles delivering siRNA that achieved about 85% in vivo MUC5AC knockdown, outperforming prior approaches. Standard FDA-approved LNP carriers paradoxically increased MUC5AC via inflammatory effects, underscoring the need for noninflammatory delivery systems. In house dust mite–induced asthmatic mice, siMuc5ac-LNPs reduced airway inflammation and obstruction with durable preventive benefit. The lead formulation also suppressed MUC5AC secretion in COPD patient–derived airway organoids, supporting broader application to mucous obstructive lung diseases.
Dupilumab-treated atopic dermatitis patients show residual Th17 and innate activation with persistent TSLP elevation
In 89 adults with moderate-to-severe atopic dermatitis, dupilumab-treated patients had higher plasma IL-17A and TNF-α than healthy controls at baseline conditions. Both dupilumab-treated and untreated AD patients showed elevated TSLP and low IFN-γ versus controls, indicating ongoing epithelial stress and Th2 skewing. Upon stimulation, IL-23 levels were lower in both AD groups than controls, while IL-6 levels remained higher, suggesting persistent innate activation. These findings confirm dupilumab does not normalize immune balance and support considering adjunctive pathways such as Th17, TSLP, or IL-6 in partial responders.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.